Literature DB >> 30382443

Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study.

Adi Aran1, Hanoch Cassuto2, Asael Lubotzky3, Nadia Wattad3, Esther Hazan3.   

Abstract

Anecdotal evidence of successful cannabis treatment in autism spectrum disorder (ASD) are accumulating but clinical studies are lacking. This retrospective study assessed tolerability and efficacy of cannabidiol-rich cannabis, in 60 children with ASD and severe behavioral problems (age = 11.8 ± 3.5, range 5.0-17.5; 77% low functioning; 83% boys). Efficacy was assessed using the Caregiver Global Impression of Change scale. Adverse events included sleep disturbances (14%) irritability (9%) and loss of appetite (9%). One girl who used higher tetrahydrocannabinol had a transient serious psychotic event which required treatment with an antipsychotic. Following the cannabis treatment, behavioral outbreaks were much improved or very much improved in 61% of patients. This preliminary study supports feasibility of CBD-based cannabis trials in children with ASD.

Entities:  

Keywords:  Autism spectrum disorder; Cannabidiol; Disruptive behavior; Medical cannabis; Medical marijuana

Mesh:

Substances:

Year:  2019        PMID: 30382443     DOI: 10.1007/s10803-018-3808-2

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN: 0162-3257


  33 in total

1.  DOCK4 regulates ghrelin production in gastric X/A-like cells.

Authors:  Y Huang; Y Yang; Y Zhao; D Guo; L Chen; L Shi; G Xu
Journal:  J Endocrinol Invest       Date:  2022-03-17       Impact factor: 4.256

Review 2.  Pharmacotherapy of Disruptive Behaviors in Children with Intellectual Disabilities.

Authors:  Gabrielle E Hodgins; Kristen Winsor; Jarrett Barnhill
Journal:  Paediatr Drugs       Date:  2022-07-04       Impact factor: 3.930

Review 3.  Cannabidiol for the treatment of autism spectrum disorder: hope or hype?

Authors:  João F C Pedrazzi; Frederico R Ferreira; Danyelle Silva-Amaral; Daniel A Lima; Jaime E C Hallak; Antônio W Zuardi; Elaine A Del-Bel; Francisco S Guimarães; Karla C M Costa; Alline C Campos; Ana C S Crippa; José A S Crippa
Journal:  Psychopharmacology (Berl)       Date:  2022-07-29       Impact factor: 4.415

4.  Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications.

Authors:  Richard Holdman; Daniel Vigil; Kelsey Robinson; Puja Shah; Alexandra Elyse Contreras
Journal:  Cannabis Cannabinoid Res       Date:  2021-08-24

Review 5.  The Autism-Psychosis Continuum Conundrum: Exploring the Role of the Endocannabinoid System.

Authors:  Marco Colizzi; Riccardo Bortoletto; Rosalia Costa; Sagnik Bhattacharyya; Matteo Balestrieri
Journal:  Int J Environ Res Public Health       Date:  2022-05-05       Impact factor: 4.614

6.  A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the USA from 2016 to 2019.

Authors:  Sebastian Jugl; Aimalohi Okpeku; Brianna Costales; Earl J Morris; Golnoosh Alipour-Haris; Juan M Hincapie-Castillo; Nichole E Stetten; Ruba Sajdeya; Shailina Keshwani; Verlin Joseph; Yahan Zhang; Yun Shen; Lauren Adkins; Almut G Winterstein; Amie Goodin
Journal:  Med Cannabis Cannabinoids       Date:  2021-02-25

Review 7.  The Role of Cannabidiol in Neurological Disorders.

Authors:  Sirichai Chayasirisobhon
Journal:  Perm J       Date:  2021-05

8.  Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis.

Authors:  Nir Treves; Noa Mor; Karel Allegaert; Hely Bassalov; Matitiahu Berkovitch; Orit E Stolar; Ilan Matok
Journal:  Sci Rep       Date:  2021-12-06       Impact factor: 4.379

9.  Use of Cannabis in Fetal Alcohol Spectrum Disorder.

Authors:  Gideon Koren; Rana Cohen; Ornie Sachs
Journal:  Cannabis Cannabinoid Res       Date:  2021-02-12

Review 10.  Cannabidiol and Neurodevelopmental Disorders in Children.

Authors:  Keith A Kwan Cheung; Murray D Mitchell; Helen S Heussler
Journal:  Front Psychiatry       Date:  2021-05-21       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.